Unify insights to accelerate drug development and achieve development milestones. Partner with Certara to unlock your pipeline’s potential.
Learn more
Certara collaborates with leading biotech, pharma, and CRO partners to tackle complex challenges, deliver innovation, and shape the future of healthcare.
Learn more
Join a global leader transforming the future of drug development. Explore opportunities to innovate, grow, and make a difference in transforming lives.
Visit careers siteA diversity of equations is available for the estimation of liver volume (LV), derived from studies in populations of ethnically homogeneous individuals and using a variety of methods of measurement….
The in vitro characterisation of a mechanism-based enzyme inactivator (MBEI) includes determination of the maximum inactivation rate constant (kinact), the inactivator concentration that produces half-maximal rate of inactivation (KI), and…
The purpose of this study was to evaluate the value of model-based, quantitative decision making during the development of gemcabene, a novel lipid-altering agent. The decisions were driven by a…
Ciclesonide is a novel and effective inhaled corticosteroid for the treatment of asthma that is converted into the active metabolite C21-desisobutyryl-ciclesonide (des-CIC) in the lung. The objectives of this analysis…
A novel model-based meta-analysis was used to quantify the dose-response relationship of sumatriptan and eletriptan for the proportion of patients that achieve migraine pain relief up to 4 h after…
Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. The objective of this study was to develop a…
Dibutylphthalate (DBP) can cause adverse effects on the developing male reproductive tract when administered late in gestation to pregnant rats. The objectives of this study were to evaluate the metabolism…
Drug/metabolite ratios (MRs) are used as in vivo markers of enzyme activity. The ratios are potentially confounded by the renal clearance of the drug (urine-based MRs) or metabolite (plasma-based MRs)….
Recently, Andersson et al. (2004) reported that quantitative predictions of hepatic clearance from in vitro CLint values using the “well- stirred liver” model were not useful. Over-prediction of in vivo…
Recently, von Richter et al measured the content of cytochrome P450 (CYP) 3A in paired samples of human enterocytes and liver tissue. We now report calculations that we believe enhance…
© 2025 Certara. All Rights Reserved. | Privacy policy